Jean Jacques Bienaime Purchases 1,000 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Jean Jacques Bienaime acquired 1,000 shares of the stock in a transaction on Monday, June 15th. The shares were purchased at an average price of $10.19 per share, for a total transaction of $10,190.00. Following the transaction, the director directly owned 17,592 shares in the company, valued at approximately $179,262.48. This trade represents a 6.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, April 15th, Jean Jacques Bienaime bought 1,000 shares of Keros Therapeutics stock. The stock was acquired at an average cost of $11.70 per share, with a total value of $11,700.00.

Keros Therapeutics Stock Performance

KROS stock opened at $10.69 on Friday. The company’s 50-day simple moving average is $11.10 and its 200 day simple moving average is $14.70. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55. The company has a market capitalization of $211.46 million, a PE ratio of -3.55 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The business had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, analysts forecast that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on KROS. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and a consensus price target of $20.40.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares during the period. UBS Group AG lifted its holdings in shares of Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after acquiring an additional 1,091 shares during the period. Strs Ohio boosted its position in shares of Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after acquiring an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new position in Keros Therapeutics in the fourth quarter valued at approximately $29,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.